MEDIPOST completed Phase 1 and 2 clinical trials with its ‘PNEUMOSTEM^®’ developed for treating bronchial pulmonary dysplasia in premature babies.

On June 15, MEDIPOST completed its final clinical injection of ‘PNEUMOSTEM^®’ on low-birth-weight (LBW) infants at Rush University Medical Center in Chicago and found no abnormalities were found during a 2-week monitoring period.

MEDIPOST has been conducting clinical trials on 12 patients since March 2015 and completed the trial injections 3 months earlier than the previously planned schedule.

MEDIPOST will be monitoring the patients to verify the safety and efficacy of ‘PNEUMOSTEM^®’ and submit an analysis to FDA.